CN104136081B - 再活化潜伏hiv病毒的巨大戟二萜醇衍生物 - Google Patents

再活化潜伏hiv病毒的巨大戟二萜醇衍生物 Download PDF

Info

Publication number
CN104136081B
CN104136081B CN201380012133.4A CN201380012133A CN104136081B CN 104136081 B CN104136081 B CN 104136081B CN 201380012133 A CN201380012133 A CN 201380012133A CN 104136081 B CN104136081 B CN 104136081B
Authority
CN
China
Prior art keywords
formula
cells
ingenol
derivatives
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380012133.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104136081A (zh
Inventor
L.F.皮亚诺维斯基
A.塔努里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazonia Fitomedicamentos Ltda
Original Assignee
Amazonia Fitomedicamentos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BR102012004739A external-priority patent/BR102012004739A2/pt
Priority claimed from BR102012006549A external-priority patent/BR102012006549A2/pt
Application filed by Amazonia Fitomedicamentos Ltda filed Critical Amazonia Fitomedicamentos Ltda
Publication of CN104136081A publication Critical patent/CN104136081A/zh
Application granted granted Critical
Publication of CN104136081B publication Critical patent/CN104136081B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G8/00—Condensation polymers of aldehydes or ketones with phenols only
    • C08G8/28—Chemically modified polycondensates
    • C08G8/30—Chemically modified polycondensates by unsaturated compounds, e.g. terpenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380012133.4A 2012-03-02 2013-03-01 再活化潜伏hiv病毒的巨大戟二萜醇衍生物 Expired - Fee Related CN104136081B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
BR102012004739A BR102012004739A2 (pt) 2012-03-02 2012-03-02 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de travamento e método para a reativação do vírus hiv latente
BRBR1020120047390 2012-03-02
BR1020120047390 2012-03-02
BR102012006549A BR102012006549A2 (pt) 2012-03-23 2012-03-23 uso de um ou mais derivados de ingenol, associação farmacêutica, composição farmacêutica, adjuvante, método de tratamento e método para a reativação do vírus hiv latente
BRBR1020120065495 2012-03-23
BR1020120065495 2012-03-23
PCT/BR2013/000063 WO2013126980A1 (pt) 2012-03-02 2013-03-01 Derivados de ingenol na reativação de vírus hiv latente

Publications (2)

Publication Number Publication Date
CN104136081A CN104136081A (zh) 2014-11-05
CN104136081B true CN104136081B (zh) 2018-05-15

Family

ID=49081479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380012133.4A Expired - Fee Related CN104136081B (zh) 2012-03-02 2013-03-01 再活化潜伏hiv病毒的巨大戟二萜醇衍生物

Country Status (13)

Country Link
US (1) US10105339B2 (https=)
EP (1) EP2821105B1 (https=)
JP (1) JP6280510B2 (https=)
CN (1) CN104136081B (https=)
AU (1) AU2013225633B2 (https=)
CA (1) CA2864995C (https=)
ES (1) ES2683726T3 (https=)
IL (1) IL234404A (https=)
IN (1) IN2014MN01911A (https=)
MX (1) MX359300B (https=)
NZ (1) NZ628408A (https=)
RU (1) RU2609512C2 (https=)
WO (1) WO2013126980A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102012028120B8 (pt) * 2012-11-01 2022-08-02 Amazonia Fitomedicamentos Ltda Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
WO2016022358A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Compositions and methods for reactivating latent viral infections
CA2984991A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
WO2016191836A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191837A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
CN105079323B (zh) * 2015-09-15 2019-08-23 北京工业大学 几种中药提取物在hiv潜伏再激活治疗中的应用
CN106928063B (zh) 2015-12-31 2020-09-01 上海鑫昊生物科技有限公司 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用
WO2017130156A1 (en) 2016-01-27 2017-08-03 Glaxosmithkline Intellectual Property (No.2) Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
CN109912419A (zh) * 2017-12-13 2019-06-21 复旦大学 巨大戟烷型二萜及其在制备抗艾滋病毒药物中的用途
CN110251495B (zh) * 2018-03-12 2022-05-31 重庆医科大学 20-脱氧巨大戟二萜醇在制备抑制hbv复制的药物中的应用
WO2020159941A1 (en) * 2019-01-28 2020-08-06 Xyphos Biosciences Inc. Modified non-natural nkg2d ligands that selectively deliver attached heterologous molecules to non-natural nkg2d receptors on car-cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07165600A (ja) * 1993-10-18 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
JP2003171349A (ja) * 2001-08-06 2003-06-20 Univ Nihon 新規なジテルペン類、及びこれを用いた組成物、抗炎症剤、抗癌剤
US20090142421A1 (en) * 2005-06-28 2009-06-04 Amazonia Fitomedicamentos Ltda. Active fraction of a polar solvent extract from the latex of euphorbiaceae plants
SI2152261T1 (sl) 2007-04-30 2016-05-31 Leo Laboratories Limited Zdravljenje viralno induciranih lezij
WO2011086424A1 (en) 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds mixtures as concomitant anti-cancer, anti-inflammatory and anti-pain agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
WO2011086423A1 (en) * 2010-01-15 2011-07-21 Amazonia Fitomedicamentos Ltda Pharmaceutical use of multicyclic compounds as anti-aids agents

Also Published As

Publication number Publication date
US20150030638A1 (en) 2015-01-29
RU2609512C2 (ru) 2017-02-02
IL234404A (en) 2017-09-28
CN104136081A (zh) 2014-11-05
EP2821105A4 (en) 2015-11-04
EP2821105A8 (en) 2015-04-29
RU2014139825A (ru) 2016-04-20
ES2683726T3 (es) 2018-09-27
MX359300B (es) 2018-09-21
HK1203872A1 (en) 2015-11-06
JP6280510B2 (ja) 2018-02-14
NZ628408A (en) 2017-09-29
AU2013225633B2 (en) 2017-11-23
CA2864995C (en) 2016-12-06
CA2864995A1 (en) 2013-09-06
EP2821105A1 (en) 2015-01-07
WO2013126980A1 (pt) 2013-09-06
EP2821105B1 (en) 2018-05-23
AU2013225633A1 (en) 2014-08-28
MX2014010463A (es) 2014-10-13
IN2014MN01911A (https=) 2015-07-10
US10105339B2 (en) 2018-10-23
JP2015508782A (ja) 2015-03-23

Similar Documents

Publication Publication Date Title
CN104136081B (zh) 再活化潜伏hiv病毒的巨大戟二萜醇衍生物
KR101830715B1 (ko) Hiv 감염을 치료하기 위한 약학적 조합물
Kumari et al. Highly active antiretroviral therapy for treatment of HIV/AIDS patients: current status and future prospects and the Indian scenario
US5977086A (en) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
US20230011398A1 (en) Combination therapy approach to eliminate hiv infections
US6787573B2 (en) Antiviral therapy
Stuyver et al. Potent antiviral effect of Reverset™ in HIV-1-infected adults following a single oral dose
EP1194141B1 (en) Antiviral therapy
HK1203872B (en) Ingenol derivatives in the reactivation of latent hiv
US11247996B2 (en) Small molecule inhibitors for transcription factors
KR20140144176A (ko) 잠복중인 hiv 바이러스의 재활성화에서 인게놀 유도체
CN114980885A (zh) 治疗hiv-1感染的方法
WO2025098496A1 (en) Pharmaceutical composition and methods for treating hiv-1 infection
US20140227335A1 (en) Virucidal small molecule and uses thereof
EP1263429B1 (en) Antiviral therapy
Basak Antiretroviral Therapy of AIDS
Guvenc The impact of heptose phosphates on HIV latency and human immune responses
ZA200200143B (en) Antiviral therapy.
WO1999047146A1 (en) Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
Chen et al. Characterisation of novel anti-HIV/tuberculosis natural product analogues
Tenneti The Characteristics of HIV Patients who are Long-term Responders to Nevirapine
WO2017060524A1 (en) (e)-n-(2-aminophenyl)-3-(1-((4-(1-methyl-1h-pyrazol-4-yl)phenyl)sulfonyl)-1h-pyrrol-3-yl)acrylamide for the treatment of latent viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180515

Termination date: 20210301